Revolution Medicines, INC 8-K filings

Revolution Medicines announced robust second quarter 2026 results, highlighting U.S. FDA acceptance of its New Drug Application for daraxonrasib and promising clinical data across multiple oncology indications.

Revolution Medicines announced first quarter 2026 financial results, highlighting positive Phase 3 trial data for daraxonrasib in pancreatic cancer and a significant capital raise.

Revolution Medicines, Inc. has issued $500 million in 0.50% convertible senior notes due 2033 to fund general corporate purposes.

Revolution Medicines, Inc. has successfully priced a $1.5 billion common stock offering and a $500 million convertible note offering to fund general corporate purposes.

Revolution Medicines announced statistically significant and clinically meaningful improvements in progression-free and overall survival for daraxonrasib in a Phase 3 pancreatic cancer trial.

Revolution Medicines announced its full year 2025 financial results and provided an update on its broad late-stage oncology pipeline, including five ongoing Phase 3 trials and plans for three more.

Revolution Medicines announced its third quarter 2025 financial results and provided updates on its late-stage oncology pipeline, including significant progress in RAS-addicted cancer trials.

Revolution Medicines announced the FDA granted a non-transferrable priority review voucher for its drug daraxonrasib under the Commissioners National Priority Voucher pilot program.

Revolution Medicines announced promising clinical data for daraxonrasib in both first-line and second-line metastatic RAS-mutant pancreatic cancer, supporting progression to a Phase 3 trial.

Revolution Medicines reports Q2 2025 financial results, highlights progress in RAS-addicted cancer therapies, and secures $2 billion funding from Royalty Pharma.

Revolution Medicines, Inc. announced the successful election of four Class II directors, ratification of PricewaterhouseCoopers LLP as independent auditors, and advisory approval of executive compensation at its 2025 annual meeting of stockholders.

Revolution Medicines, a late-stage oncology company, has entered into a $2 billion flexible funding agreement with Royalty Pharma, comprising synthetic royalty monetization and corporate debt, to support its independent global development and commercialization strategy for its RAS(ON) inhibitor portfolio.

Barbara Weber, M.D., has resigned from the Board of Directors of Revolution Medicines, Inc., effective prior to the 2025 annual meeting, citing the activation of a clinical study with Tango Therapeutics, Inc.

Revolution Medicines announces encouraging clinical data from its RAS(ON) inhibitor portfolio and reports its first quarter 2025 financial results, highlighting progress in pivotal trials and commercialization efforts.

Revolution Medicines reports strong financial results for 2024, highlighted by significant progress in clinical trials for its RAS-addicted cancer therapies and a substantial increase in cash reserves.

Revolution Medicines successfully closed a public offering, raising approximately $823 million through the sale of common stock and pre-funded warrants.

Revolution Medicines reports positive clinical data for its drug candidates RMC-6236 and RMC-6291 in various cancer types, including pancreatic, lung, and colorectal cancers.

Revolution Medicines reported encouraging clinical results for its RAS(ON) inhibitors and provided a financial update for the third quarter of 2024.

Revolution Medicines reports positive preliminary safety and activity data for its RMC-9805 cancer drug in patients with solid tumors harboring KRAS G12D mutations.

Revolution Medicines reports positive clinical trial results for RMC-6236, showing encouraging progression-free and overall survival rates in patients with advanced pancreatic cancer.

Revolution Medicines announced the appointment of Frank Clyburn to its board of directors, along with its second quarter 2024 financial results and updates on its clinical programs.

Revolution Medicines announced updated clinical data for RMC-6236 in pancreatic cancer and provided a financial update, projecting a net loss between $560 million and $600 million for 2024.

Revolution Medicines held its 2024 annual meeting, where stockholders elected three Class I directors, ratified the appointment of PricewaterhouseCoopers LLP as the independent auditor, and approved executive compensation on an advisory basis.

Revolution Medicines announced its first quarter 2024 financial results and provided an update on the progress of its clinical programs, particularly focusing on its lead drug candidate RMC-6236.

Revolution Medicines announced its 2023 financial results and provided updates on its clinical programs, highlighting progress with its RAS(ON) inhibitors and a strong cash position following the EQRx acquisition.